/Companies

Tridek One

Paris, FR · Founded 2018 · 14 employees on LinkedIn · 5 known investors

Find your way into Tridek One

Sign up to see every warm intro you have to Tridek One

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Tridek One team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases. Its lead program is a CD31×GPVI bispecific antibody for thromboinflammatory cardiovascular diseases, aiming to provide antithrombotic and anti-inflammatory effects while minimizing bleeding risk.

Investors · 5

Frequently asked questions

What does Tridek One do?
Tridek-One Therapeutics develops bispecific antibodies that agonize the CD31 ITIM inhibitory checkpoint receptor to modulate immune cell activation for inflammatory and autoimmune diseases. Its lead program is a CD31×GPVI bispecific antibody for thromboinflammatory cardiovascular diseases, aiming to provide antithrombotic and anti-inflammatory effects while minimizing bleeding risk.
Who are Tridek One's investors?
Tridek One's investors include Advent Life Sciences, Bioqube Ventures, Bpifrance, Pureos Bioventures, AdBio partners.
Where is Tridek One headquartered?
Tridek One is headquartered in Paris, FR.